Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity

Drug Resistance Updates

Volumn 1, Issue 1, 1998, Pages 21-28

  Arts, Eric J ^a   Quiñones Mateu, Miguel E ^a   Albright, Jamie L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002747874     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80211-2     Document Type: Review

References (75)

1. Arts E.J., and Wainberg M.A. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 40 (1996) 527-540
2. de Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type I (HIV-I) infections: strategies to overcome drug resistance development. Med Res Rev 16 (1996) 125-157
3. McDonald C.K., and Kuritzkes D.R. Human immunodeficiency virus type I protease inhibitors. Arch Intern Med 157 (1997) 951-959
4. Wainberg M.A., Gu Z., Gao Q., et al. Clinical correlates and molecular basis of HIV drug resistance. J AIDS 6 (1993) S36-S46
5. Mellors J.W., Rinaldo Jr. C.R., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-I infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
6. Richman D.D. Drug resistance in relation to pathogenesis. AIDS 9 (1995) S49-S53
7. Merrill D.P., Moonis M., Chou T.C., and Hirsch M.S. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type I replication in vitro. J Infect Dis 173 (1996) 355-364
8. Lange J.M. Current problems and the future of antiretroviral drug trials. Science 276 (1997) 548-550
9. Johnson V.A. Combination therapy for HIV-I infection - overview: preclinical and clinical analysis of antiretroviral combinations. Antivir Res 29 (1996) 35-39
10. Larder B.A., Darby G., and Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged. Science 243 (1989) 1731-1734
11. Larder B.A., and Kemp S.D. Multiple mutations in HIV-I reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 (1989) 1155-1158
12. Rooke R., Tremblay M., Soudeyns H., et al. Isolation of drug-resistant variants of HIV-I from patients on long-term zidovudine therapy. AIDS 3 (1989) 411-415
13. Coates J.A., Cammack N., Jenkinson H.J., et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 36 (1992) 733-739
14. Balzarini J. Anti-retroviral and pharmacological properties of 9-(2-phosphonylmethoxyethyl) adenine (PMEA). Adv Expt Med Biol 370 (1994) 459-464
15. Daluge S.M., Good S.S., Faletto M.B., et al. 1592U89, a novel carbocylic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 41 (1997) 1082-1093
16. Zimmerman T.P., Mahony W.B., and Prus K.L. 3′-Azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 262 (1987) 5748-5754
17. Furman P.A., Fyfe J.A., St Clair M.H., et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83 (1986) 8333-8337
18. Lavie A., Schlichting I., Vetter I.R., Konrad M., Reinstein J., and Goody R.S. The bottleneck in AZT activation. Nature Med (1997) 922-925
19. In press. Lavie A., et al. Crystal structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. Nature Struct Biol (1997)
20. St. Clair M.H., Richards C.A., Spector T., et al. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31 (1987) 1972-1977
21. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-I entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 (1990) 213-222
22. Geleziunas R., Arts E.J., Boulerice F., Goldman H., and Wainberg M.A. Effect of 3′-azido-3′-deoxythymidine on human immunodeficiency virus type-I replication in human fetal brain macrophages. Antimicrob Agents Chemother 37 (1993) 1305-1312
23. Arts E.J., and Wainberg M.A. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 38 (1994) 1008-1016
24. Arts E.J., Marois J.P., Gu Z., Le Grice S.F., and Wainberg M.A. Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type-I reverse transcription of minus-strand strong-stop DNA. J Virol 70 (1996) 712-720
25. Arts E.J., Li X., Gu Z., Kleiman L., Parniak M.A., and Wainberg M.A. Comparison of deoxyoligonucleotide and tRNA (Lys-3) as primers in an endogenous human immunodeficiency virus-I in vitro reverse transcription/template-switching reaction. J Biol Chem 69 (1994) 14672-14680
26. Peliska J.A., and Benkovic S.J. Mechanism of DNA strand transfer reactions catalyzed by HIV-I reverse transcriptase. Science 258 (1992) 1112-1118
27. Gao W.Y., Johns D.G., and Mitsuya H. Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2′,3′-dideoxynucleosides. Anal Biochem 222 (1994) 116-122
28. Gao W.Y., Cara A., Gallo R.C., and Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type I replication. Proc Natl Acad Sci USA 90 (1993) 8925-8928
29. Gao W.Y., Johns D.G., and Mitsuya H. Anti-human immunodeficiency virus type I activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 46 (1994) 767-772
30. Balzarini J., Herdewijn P., and De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 264 (1989) 6127-6133
31. Gao W.Y., Shirasaka T., Johns D.G., Broder S., and Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 91 (1993) 2326-2333
32. Huber H.E., McCoy J.M., Seehra J.S., and Richardson C.C. Human immunodeficiency virus I reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J Biol Chem 264 (1989) 4669-4678
33. Bebenek K., Abbotts J., Wilson S.H., and Kunkel T.A. Error-prone polymerization by HIV-I reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem 268 (1993) 10324-10334
34. Heidenreich O., Kruhoffer M., Grosse F., and Eckstein F. Inhibition of human immunodeficiency virus I reverse transcriptase by 3′-azidothymidine triphosphate. Eur J Biochem 192 (1990) 621-625
35. Reardon J.E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31 (1992) 4473-4479
36. Reardon J.E., and Miller W.H. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J Biol Chem 265 (1990) 20302-20307
37. Arts E.J., and Wainberg M.A. Human immunodeficiency virus type I reverse transcriptase and early events in reverse transcription. Adv Virus Res 46 (1996) 97-163
38. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5A resolution of HIV-I reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
39. Jacobo-Molina A., Ding J., Nanni R.G., et al. Crystal structure of human immunodeficiency virus type I reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 90 (1993) 6320-6324
40. Zhang D., Caliendo A.M., Eron J.J., et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 38 (1994) 282-287
41. Gu Z., Gao Q., Fang H., et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 38 (1994) 275-281
42. Tisdale M., Alnadaf T., and Cousens D. Combination of mutations in human immunodeficiency virus type I reverse transcriptase required for resistance to the carbocyclic nucleoside I592U89. Antimicrob Agents Chemother 41 (1997) 1094-1098
43. Gu Z., Salomon H., Cherrington J.M., et al. K65R mutation of human immunodeficiency virus type I reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine 39 (1995) 1888-1891
44. St Clair M.H., Martin J.L., Tudor-Williams G., et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-I reverse transcriptase. Science 253 (1991) 1557-1559
45. Lacey S.F., and Larder B.A. Novel mutation (V75T) in human immunodeficiency virus type I reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 38 (1994) 1428-1432
46. Gu Z., Fletcher R.S., Arts E.J., Wainberg M.A., and Parniak M.A. The K65R mutant reverse transcriptase of HIV-I cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 269 (1994) 28118-28122
47. Gu Z., Arts E.J., Parniak M.A., and Wainberg M.A. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type I shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc Natl Acad Sci USA 92 (1995) 2760-2764
48. Gao Q., Gu Z., Parniak M.A., et al. The same mutation that encodes low-level human immunodeficiency virus type-I resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37 (1993) 1390-1392
49. Gu Z., Gao Q., Li X., Parniak M.A., and Wainberg M.A. Novel mutation in the human immunodeficiency virus type I reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 66 (1992) 7128-7135
50. Tisdale M., Kemp S.D., Parry N.R., and Larder B.A. Rapid in vitro selection of human immunodeficiency virus type I resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90 (1993) 5653-5656
51. Schinazi R.F., Lloyd Jr. R.M., Nguyen M.H., et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37 (1993) 875-881
52. Wainberg M.A., Drosopoulos W.C., Salomon H., et al. Enhanced fidelity of 3TC-selected mutant HIV-I reverse transcriptase. Science 271 (1996) 1282-1285
53. Back N.K., Nijhuis M., Keulen W., et al. Reduced replication of 3TC-resistant HIV-I variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15 (1996) 4040-4049
54. Pandey V.N., Kaushik N., Rege N., Sarafianos S.G., Yadav P.N., and Modak M.J. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 35 (1996) 2168-2179
55. de Jong M.D., Veenstra J., Stilianakis N.I., et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type I RNA load suppression by zidovudine. Proc Natl Acad Sci USA 93 (1996) 5501-5506
56. Kellam P., and Larder B.A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 69 (1996) 669-674
57. Martin J.L., Wilson J.E., Haynes R.L., and Furman P.A. Mechanism of resistance of human immunodeficiency virus type I to 2′,3′-dideoxyinosine. Proc Natl Acad Sci USA 90 (1993) 6135-6139
58. Lacey S.F., Reardon J.E., Furfine E.S., et al. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 267 (1992) 15789-15794
59. Katzenstein D.A., Hammer S.M., Hughes M.D., et al. The relation of virologic and immunologic markers to clinical after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 per cubic millimeter. N Engl J Med 335 (1996) 1091-1098
60. Hammer S.M., Katzenstein D.A., Hughes M.D., et al. A trial comparing nucleoside monotherapy with combination therapy HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 335 (1996) 1081-1090
61. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348 (1996) 283-291
62. Shirasaka T., Kavlick M.F., Ueno T., et al. Emergence of human immunodeficiency virus type I variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92 (1995) 2398-2402
63. Iversen A.K., Shafer R.W., Wehrly K., et al. Multidrug-resistant human immunodeficiency virus type I strains resulting from combination antiretroviral therapy. J Virol 70 (1996) 1086-1090
64. Shafer R.W., Winters M.A., Jellinger R.M., and Merigan T.C. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis 174 (1996) 448-449
65. Abst. 58. Johnson V.A., Kuritzkes D.R., Richman D.D., et al. HIV-I drug resistance and virological failure during combination therapy with nevirapine, zidovudine, and didanosine. International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication. St. Petersburg, FA (1997)
66. Domingo E., Menendez-Arias L., Quinones-Mateu M.E., et al. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 48 (1997) 99-128
67. Caliendo A.M., Savara A., An D., DeVore K., Kaplan J.C., and D'Aquila R.T. Effects of zidovudine-selected human immunodeficiency virus type I reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 70 (1996) 2146-2153
68. Ueno T., and Mitsuya H. Comparative enzymatic study of HIV-I reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36 (1997) 1092-1099
69. Abst. 10. Quiñones-Mateu M.E., Albright J.L., Marois J.P., et al. A unique mechanism for zidovudine-resistance and evidence for a zidovudine-mediated cross-resistance to other nucleoside analogues by zidovudine-resistant viruses. International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication. St. Petersburg, FA (1997)
70. Submitted. Arts E.J., Quiñones-Mateu M.E., Albright J.L., Marois J.P., and Wainberg M.A. Zidovudine mediates resistance to itself and other nucleoside analogs by zidovudine-resistant human immunodeficiency virus type I (1997)
71. Medeiros A.A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 24 (1997) S19-S45
72. Mosser A.G., and Rueckert R.R. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol 67 (1993) 1246-1254
73. Mesters J.R., Zeef L.A., Hilgenfeld R., de Graaf J.M., Kraal B., and Bosch L. The structural and functional basis for the kirromycin resistance of mutant EF-Tu species in Escherichia coli. EMBO J 13 (1994) 4877-4885
74. Ruiz L., Romeu J., Martinez-Picado J., et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV +3TC) combination therapy in patients previously treated with ZDV +ddC. AIDS 10 (1996) F61-F66
75. Larder B.A., Kemp S.D., and Harrigan P.R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 (1995) 696-699